Xconomy: Robotics and A.I.

National
Bio Roundup: COVID-19 Pact, Gavreto Approval, Generative Biology & More

1.
Bio Roundup: COVID-19 Pact, Gavreto Approval, Generative Biology & More | National
2.
Generate Bio Aims to Reveal Nature’s Protein Secrets, Create New Drugs | Boston
3.
Two Days, Six IPOs, and $1B Raised for Biotech Research & More | National
4.
Data Quantity, Complexity Drives Use of AI in Drug Discovery and Testing | San Francisco
5.
Akili Interactive’s Video Game for ADHD Gets the FDA All Clear | Boston
6.
Biotech “Mapmaker” Immunai Launches With $20M to Chart the Immune System | New York

Pliant Pushes Forward With IPO Plans to Back Fibrosis Drug Studies
Frank Vinluan | San Francisco
Lantern Pharma IPO File Illuminates Plan to “Rescue” Failed Cancer Drugs
Frank Vinluan | Texas
Bio Roundup: Pandemic Declared, Rubius Restarts, Kymera’s Cash & More
Frank Vinluan | National
Titan Medical’s Cash Crunch Stalls Plans to Get Surgical Robot to FDA
Frank Vinluan | National
Biotech Roundup: Gottlieb v. Juul, Solid Slumps, Avidity Gets $100M & More
Sarah de Crescenzo | National
Bio Roundup: Feds Sue Gilead, Biogen Eyes China, CRISPR’d Kidneys & More
Frank Vinluan | National
AI Can Unlock Health Data’s Potential, But Access Is Still Difficult
Jeff Bauter Engel | Wisconsin
AstraZeneca Chooses China for R&D and AI Centers, $1B Biotech Fund
Gareth Macdonald | National
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
Frank Vinluan | National

Read More Posts ›

Underwriters and Partners

Xconomy Insight

From Our Editors · Podcast
Xcelerating Life Sciences Philadelphia: The Highlights Podcast
Becoming the Cell & Gene Therapy Hub

Sponsored · Whitepaper
The Importance of Early Key Opinion Leader Outreach in the Biologics & Biosimilars Marketplace
Acknowledging various stakeholder networks and regulatory environment variances is essential to uncover the right decision-makers in support of biologics or biosimilars
IBM Watson

Sponsored · Whitepaper
Decentralized Clinical Trials: The Call for a New Paradigm
Virtual/hybrid trials and decentralized research can better integrate healthcare into patients’ lives and accelerate approval of new medications
PRA Health Sciences

Xconomy on Demand

We offer a number of ways to subscribe for free!